$25.93
0.31% yesterday
Nasdaq, Dec 24, 08:23 pm CET
ISIN
NL00150005Y4
Symbol
PHVS

Pharvaris NV Stock price

$25.93
+0.54 2.13% 1M
+8.73 50.76% 6M
+6.76 35.26% YTD
+7.10 37.71% 1Y
+16.02 161.65% 3Y
+5.93 29.65% 5Y
+5.93 29.65% 10Y
+5.93 29.65% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.08 0.31%
ISIN
NL00150005Y4
Symbol
PHVS
Industry

Key metrics

Basic
Market capitalization
$1.7b
Enterprise Value
$1.3b
Net debt
positive
Cash
$387.7m
Shares outstanding
65.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.5
Financial Health
Equity Ratio
91.9%
Return on Equity
-50.1%
ROCE
-53.5%
ROIC
-2,717.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-196.5m | $-192.8m
EBIT
$-197.0m | $-194.9m
Net Income
$-192.8m | $-220.5m
Free Cash Flow
$-158.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-30.9% | -12.6%
EBIT
-30.9% | -13.6%
Net Income
-23.8% | -39.6%
Free Cash Flow
-22.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.1
FCF per Share
$-2.4
Short interest
0.8%
Employees
114
Rev per Employee
$0.0
Show more

Is Pharvaris NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Pharvaris NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Pharvaris NV forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Pharvaris NV forecast:

Buy
89%
Hold
11%

Financial data from Pharvaris NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 53 53
9% 9%
-
- Research and Development Expense 143 143
41% 41%
-
-197 -197
31% 31%
-
- Depreciation and Amortization 0.48 0.48
66% 66%
-
EBIT (Operating Income) EBIT -197 -197
31% 31%
-
Net Profit -193 -193
24% 24%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pharvaris NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pharvaris NV Stock News

Positive
The Motley Fool
16 days ago
Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris in the third quarter. Saturn V now holds 886,332 PHVS shares valued at $22.1 million.
Neutral
Seeking Alpha
22 days ago
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript
Positive
Investors Business Daily
22 days ago
Pharvaris stock surged Wednesday — and KalVista reversed higher — on promising test results for an HAE treatment.
More Pharvaris NV News

Company Profile

Pharvaris NV is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans G. C. P. Schikan and Anne Lesage on September 30, 2015 and is headquartered in Leiden, Netherlands.

Head office Netherlands
CEO Berndt Modig
Employees 114
Founded 2015
Website pharvaris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today